In 2010, ~67,500 SAVRs were performed in the U.S.

Clark M, Duhay F, Thompson A, Keyes M, et al. Clinical and Economic Outcomes After Surgical Aortic Valve Replacement in Medicare Patients. Risk Manag Healthc Policy. 2012; 2012(5). https://www.dovepress.com/clinical-and-economic-outcomes-after-surgical-aortic-valve-replacement-peer-reviewed-article-RMHP

Title: Clinical and Economic Outcomes After Surgical Aortic Valve Replacement in Medicare Patients
Publication: Risk Manag Healthc Policy
Publication Date: 2012
Authors: Clark M, Duhay F, Thompson A, Keyes M, et al.
Volume & Issue: Volume 2012, Issue 5
Pages: 117-26
URL: Read Full Resource

TAVR Success in sSAS Patients
A study of severe symptomatic aortic stenosis (sSAS) patients who received transcatheter aortic valve replacement (TAVR) found 30-day mortality of 2.2% for those who were high risk of surgical mortality/inoperable,… [ Get More Details ]
Undertreatment of patients with sSAS
AS is often undertreated — one study found that 56% of severe symptomatic aortic stenosis (sSAS) patients referred to a cardiothoracic surgeon were not operated on. [ Get More Details ]
Life expectancy and quality of life gains from AVR
A study of 4,617 patients who underwent aortic valve replacement (AVR) over a period of 20 years found significant gains in life expectancy and quality of life — 43,166 net life-years… [ Get More Details ]
Survival Rates of SAS Patients with and without SAVR
Patients with severe aortic stenosis (SAS) ages 80+ who underwent surgical aortic valve replacement (SAVR) have 1-year, 2-year, and 5-year survival rates of 87%, 78%, and 68% respectively — compared with… [ Get More Details ]
Cost-effectiveness of TAVR in sSAS patients
Patients with severe symptomatic aortic stenosis (sSAS) considered to be at high surgical risk who underwent transcatheter aortic valve replacement (TAVR) experienced lifetime incremental cost-effectiveness ratios of $55,090 per QALY… [ Get More Details ]